Antibiotics With Bacteria-Specific, Rather Than Site-Specific, Indication Headed To US FDA

 
• By Joseph Haas
  
PS2110_Acinetobacter Baumannii_1200-BDGNT6 (Alamy)
Up close, Acinetobacter Baumannii may not look it much, but developing treatments has taken a lot of industry-regulator collaboration. • Source: Alamy

More from Review Pathways

More from Pathways & Standards